Loading...
Approval Summary: Imatinib Mesylate in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors
On December 19, 2008, the U.S. Food and Drug Administration approved imatinib mesylate tablets for oral use (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the adjuvant treatment of adult patients following complete gross resection of Kit(+) (CD117(+)) gastrointestinal stromal...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AlphaMed Press
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227955/ https://ncbi.nlm.nih.gov/pubmed/20200041 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0120 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|